Meeting
2018 ASCO Annual Meeting
Phase 1 multicenter trial to assess the maximum tolerated dose, safety, pharmacokinetics, and pharmacodynamics of pazopanib in combination with irinotecan and temozolomide (PAZIT) for children and young adults with advanced sarcoma.
Authors
Kieuhoa Tran Vo
University of California San Francisco, San Francisco, CA
Kieuhoa Tran Vo , Jennifer Gibney Michlitsch , Avanthi T Shah , Janel Long-Boyle , Mi-Ok Kim , Clay Gustafson , Alejandro Sweet-Cordero , Katherine K. Matthay , Steven G. DuBois
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT03139331
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS10576)
DOI
10.1200/JCO.2018.36.15_suppl.TPS10576
Abstract #
TPS10576
Poster Bd #
248b
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase I trial of pazopanib in combination with irinotecan and temozolomide (PAZIT) for children and young adults with advanced sarcoma.
First Author: Kieuhoa T. Vo
Poster
2019 ASCO Annual Meeting
A phase I study of pazopanib with weekly paclitaxel and carboplatin in advanced solid tumors.
First Author: Nancy Chan
Poster
2016 ASCO Annual Meeting
A first in human phase I study of receptor tyrosine kinase (RTK) inhibitor MGCD516 in patients with advanced solid tumors.
First Author: Todd Michael Bauer
Poster
2015 ASCO Annual Meeting
First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737).
First Author: Philippe L. Bedard